Novavax Inc (NVAX)

[TRUISM]

Short Interest in Novavax Rises By 5.9% (NVAX)
Posted by Ethan Ryder on Oct 11th, 2014

Click For Link




Novavax (NASDAQ:NVAX) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 34,471,947 shares, an increase of 5.9% from the September 15th total of 32,542,926 shares, StockRatingsNetwork.com reports. Currently, 15.1% of the shares of the companyare sold short. Based on an average daily volume of 3,093,812 shares, the short-interest ratio is presently 11.1 days.

A number of research firms have recently commented on NVAX. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Novavax in a research note on Tuesday. They set an “overweight” rating and a $7.00 price target on the stock.

Separately, analysts at Piper Jaffray raised their price target on shares of Novavax from $9.00 to $10.50 in a research note on Wednesday, September 24th. They now have an “overweight” rating on the stock. Finally, analysts at Wedbush initiated coverage on shares of Novavax in a research note on Thursday, September 18th.

They set an “outperform” rating and a $10.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, Novavax presently has a consensus rating of “Buy” and a consensus target price of $9.42.

Novavax (NASDAQ:NVAX) opened at 4.40 on Friday. Novavax has a 52-week low of $2.68 and a 52-week high of $6.95. The stock has a 50-day moving average of $4.50 and a 200-day moving average of $4.44. The company’s market cap is $1.048 billion.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The company had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.74 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 134.0% on a year-over-year basis. On average, analysts predict that Novavax will post $-0.29 earnings per share for the current fiscal year.

Novavax, Inc (NASDAQ:NVAX) is a clinical stage biopharmaceutical company.





TRUTH